BIBiogen BIIB · NASDAQ
$249.65 +2.29% (+$5.60)
- Market cap
- $36.9B
- Enterprise value
- $43.4B
- P/E
- 106.0x
- Forward P/E
- -
- PEG
- -
- P/S
- 3.6x
- P/FCF
- 15.7x
- EV/EBITDA
- 47.0x
- ROIC
- 2.7%
- Gross margin
- 70.0%
- Net margin
- 3.4%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- 7.0x
- Beta
- 0.17
- Free float
- 99.2%
About the company
Biogen Inc. (BIIB) is an American biotechnology company specializing in the research, development, and production of therapies for neurological and neurodegenerative diseases. With a portfolio of products focused on treating multiple sclerosis, Alzheimer's disease, and other neurological disorders, Biogen is one of the leading players in the neurology field. The company is known for its emphasis on scientific research and innovation, enabling it to bring groundbreaking treatment options to patients with serious health conditions. Biogen also collaborates with academic institutions and other pharmaceutical companies to expand its research and development capabilities. Biogen Inc. (BIIB) shares could be suitable for investors looking for opportunities in the biotechnology sector with a focus on neurology and neurodegenerative disease research.
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Christopher A. Viehbacher
Employees
7,500
Headquarters
Cambridge
Valuation
Is today's price reasonable?
- What speaks for it: The share price is below the Bulios Fair Price.
Growth and estimates
Is it growing, and what comes next?
- What to watch: Earnings per share fell by 25% a year over the last 3 years.
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
- What speaks for it: Out of every 100 USD of revenue, 23 USD is left as free cash.
- What to watch: Out of every 100 USD of revenue, only 3.4 USD is left as net profit.
- What to watch: It earns only 2.7 USD a year on every 100 USD of invested capital.
Financial health
Can it carry its debt?
- What to watch: Repaying its net debt would take 7.0 years of operating profit.
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number